CanSino Biologics

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Founded2009; 12 years ago (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters
Tianjin
,
China
Website

CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

History[edit]

CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2] In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR market where it raised 5.2 billion yuan (US$750 million).[3]

Vaccines[edit]

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19.[1][4] The company has previously collaborated with the National Research Council of Canada (NRC) on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[5][6]

COVID-19 vaccine development[edit]

Main article: Ad5-nCoV

AD5-nCOV, trade-named Convidecia, is a single-dose[7] viral vector COVID-19 vaccine developed by CanSino Biologics. Since late 2020, it has been in Phase III trials in Argentina,[8] Chile,[9] Mexico,[10] Pakistan,[11] Russia,[12] and Saudi Arabia[11] with 40,000 participants.

In February 2021, global data from Phase III trials and 101 COVID cases showed that the vaccine had a 65.7% efficacy in preventing moderate symptoms of COVID-19, and 91% efficacy in preventing severe disease.[13] It has similar efficacy to Johnson & Johnson's Ad26.COV2.S, another one-shot adenovirus vector vaccine with 66% efficacy in a global trial.[14][7] Its single-dose regimen and normal refrigerator storage requirement (2°to 8°C) could make it a favorable vaccine option for many countries.[14]

Convidecia is authorized for use in China,[15] Mexico,[16] Pakistan,[17] Chile, and Hungary.[18] Annual production capacity for Ad5-nCoV should reach 500 million doses in 2021.[19]

Investors[edit]

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also[edit]

References[edit]

  1. ^ a b c d e Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. ^ Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. ^ Ren, Daniel (13 August 2020). "Covid-19 vaccine maker CanSino soars in Star Market debut". South China Morning Post. Retrieved 15 August 2020. CS1 maint: discouraged parameter (link)
  4. ^ Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  5. ^ Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020. CS1 maint: discouraged parameter (link)
  6. ^ "National Research Council contribution plays key role in newly approved Ebola vaccine". National Research Council Canada. 20 March 2018. The vaccine developed by CanSino is designed to provide protection against the strain of Ebola virus that caused the 2014 outbreak.
  7. ^ a b "It's not just Johnson & Johnson: China has a single-dose COVID-19 vaccine that's 65% effective". Fortune. Retrieved 11 February 2021.
  8. ^ "Comenzará en la Argentina un nuevo estudio de vacuna recombinante contra el SARS-CoV-2". infobae (in Spanish). 14 December 2020. Retrieved 15 December 2020.
  9. ^ "Gob.cl - Article: Science Minister: "We Work With Maximum Rigor So That Science And Technology Benefit People'S Health"". Government of Chile. Retrieved 21 November 2020.
  10. ^ "Chinese Covid vaccine trials to be expanded to five more states". Mexico News Daily. 10 November 2020. Retrieved 11 November 2020.
  11. ^ a b "Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 21 October 2020.
  12. ^ Reuters Staff (7 December 2020). "Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax". Reuters. Retrieved 7 December 2020.
  13. ^ "CanSinoBIO's COVID-19 vaccine 65.7% effective in global trials, Pakistan official says". Reuters. 8 February 2021. Retrieved 8 February 2021.
  14. ^ a b "China's CanSino Covid Vaccine Shows 65.7% Efficacy". Bloomberg.com. 8 February 2021. Retrieved 10 February 2021.
  15. ^ Staff, Reuters (25 February 2021). "China approves two more domestic COVID-19 vaccines for public use". Reuters. Retrieved 26 February 2021.
  16. ^ "Mexico approves China's CanSino and Sinovac COVID-19 vaccines". Reuters. 10 February 2021.
  17. ^ Shahzad, Asif (12 February 2021). "Pakistan approves Chinese CanSinoBIO COVID vaccine for emergency use". Reuters. Retrieved 12 February 2021.
  18. ^ "China's CanSino Biologics COVID-19 vaccine receives emergency use approval in Hungary". MSN. 22 March 2021. Retrieved 22 March 2021.
  19. ^ "China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". finance.yahoo.com. Retrieved 28 February 2021.

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=CanSino_Biologics&oldid=1019419747"